299 related articles for article (PubMed ID: 26152113)
21. Clinical and pathologic aspects of basal-like breast cancers.
Fadare O; Tavassoli FA
Nat Clin Pract Oncol; 2008 Mar; 5(3):149-59. PubMed ID: 18212769
[TBL] [Abstract][Full Text] [Related]
22. Phenotypic characterization of BRCA1 and BRCA2 tumors based in a tissue microarray study with 37 immunohistochemical markers.
Palacios J; Honrado E; Osorio A; Cazorla A; Sarrió D; Barroso A; Rodríguez S; Cigudosa JC; Diez O; Alonso C; Lerma E; Dopazo J; Rivas C; Benítez J
Breast Cancer Res Treat; 2005 Mar; 90(1):5-14. PubMed ID: 15770521
[TBL] [Abstract][Full Text] [Related]
23. MicroRNA expression signatures for the prediction of BRCA1/2 mutation-associated hereditary breast cancer in paraffin-embedded formalin-fixed breast tumors.
Tanic M; Yanowski K; Gómez-López G; Rodriguez-Pinilla MS; Marquez-Rodas I; Osorio A; Pisano DG; Martinez-Delgado B; Benítez J
Int J Cancer; 2015 Feb; 136(3):593-602. PubMed ID: 24917463
[TBL] [Abstract][Full Text] [Related]
24. Prediction of BRCA2-association in hereditary breast carcinomas using array-CGH.
Joosse SA; Brandwijk KI; Devilee P; Wesseling J; Hogervorst FB; Verhoef S; Nederlof PM
Breast Cancer Res Treat; 2012 Apr; 132(2):379-89. PubMed ID: 20614180
[TBL] [Abstract][Full Text] [Related]
25. The phenotypic spectrum of basal-like breast cancers: a critical appraisal.
Fadare O; Tavassoli FA
Adv Anat Pathol; 2007 Sep; 14(5):358-73. PubMed ID: 17717437
[TBL] [Abstract][Full Text] [Related]
26. Pathologic features and immunophenotype of estrogen receptor-positive breast cancers in BRCA1 mutation carriers.
Kaplan JS; Schnitt SJ; Collins LC; Wang Y; Garber JE; Montgomery K; West RB; Krag K; Fetten K; Lincoln A; Tung NM
Am J Surg Pathol; 2012 Oct; 36(10):1483-8. PubMed ID: 22613997
[TBL] [Abstract][Full Text] [Related]
27. Distinct genomic aberration patterns are found in familial breast cancer associated with different immunohistochemical subtypes.
Melchor L; Honrado E; García MJ; Alvarez S; Palacios J; Osorio A; Nathanson KL; Benítez J
Oncogene; 2008 May; 27(22):3165-75. PubMed ID: 18071313
[TBL] [Abstract][Full Text] [Related]
28. miRNA expression profiling of 51 human breast cancer cell lines reveals subtype and driver mutation-specific miRNAs.
Riaz M; van Jaarsveld MT; Hollestelle A; Prager-van der Smissen WJ; Heine AA; Boersma AW; Liu J; Helmijr J; Ozturk B; Smid M; Wiemer EA; Foekens JA; Martens JW
Breast Cancer Res; 2013 Apr; 15(2):R33. PubMed ID: 23601657
[TBL] [Abstract][Full Text] [Related]
29. miRNA-135b Contributes to
Uva P; Cossu-Rocca P; Loi F; Pira G; Murgia L; Orrù S; Floris M; Muroni MR; Sanges F; Carru C; Angius A; De Miglio MR
Int J Med Sci; 2018; 15(6):536-548. PubMed ID: 29725243
[TBL] [Abstract][Full Text] [Related]
30. BRCA1 promoter methylation in sporadic breast tumors: relationship to gene expression profiles.
Matros E; Wang ZC; Lodeiro G; Miron A; Iglehart JD; Richardson AL
Breast Cancer Res Treat; 2005 May; 91(2):179-86. PubMed ID: 15868446
[TBL] [Abstract][Full Text] [Related]
31. Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Breast Cancer Linkage Consortium.
Lancet; 1997 May; 349(9064):1505-10. PubMed ID: 9167459
[TBL] [Abstract][Full Text] [Related]
32. Distinct genomic profiles in hereditary breast tumors identified by array-based comparative genomic hybridization.
Jönsson G; Naylor TL; Vallon-Christersson J; Staaf J; Huang J; Ward MR; Greshock JD; Luts L; Olsson H; Rahman N; Stratton M; Ringnér M; Borg A; Weber BL
Cancer Res; 2005 Sep; 65(17):7612-21. PubMed ID: 16140926
[TBL] [Abstract][Full Text] [Related]
33. Molecular features of the basal-like breast cancer subtype based on BRCA1 mutation status.
Prat A; Cruz C; Hoadley KA; Díez O; Perou CM; Balmaña J
Breast Cancer Res Treat; 2014 Aug; 147(1):185-91. PubMed ID: 25048467
[TBL] [Abstract][Full Text] [Related]
34. Deregulated microRNAs in triple-negative breast cancer revealed by deep sequencing.
Chang YY; Kuo WH; Hung JH; Lee CY; Lee YH; Chang YC; Lin WC; Shen CY; Huang CS; Hsieh FJ; Lai LC; Tsai MH; Chang KJ; Chuang EY
Mol Cancer; 2015 Feb; 14():36. PubMed ID: 25888956
[TBL] [Abstract][Full Text] [Related]
35. Enhanced RAD21 cohesin expression confers poor prognosis in BRCA2 and BRCAX, but not BRCA1 familial breast cancers.
Yan M; Xu H; Waddell N; Shield-Artin K; Haviv I; ; McKay MJ; Fox SB
Breast Cancer Res; 2012 Apr; 14(2):R69. PubMed ID: 22537934
[TBL] [Abstract][Full Text] [Related]
36. Gene-expression molecular subtyping of triple-negative breast cancer tumours: importance of immune response.
Jézéquel P; Loussouarn D; Guérin-Charbonnel C; Campion L; Vanier A; Gouraud W; Lasla H; Guette C; Valo I; Verrièle V; Campone M
Breast Cancer Res; 2015 Mar; 17():43. PubMed ID: 25887482
[TBL] [Abstract][Full Text] [Related]
37. RNA helicase DDX5 regulates microRNA expression and contributes to cytoskeletal reorganization in basal breast cancer cells.
Wang D; Huang J; Hu Z
Mol Cell Proteomics; 2012 Feb; 11(2):M111.011932. PubMed ID: 22086602
[TBL] [Abstract][Full Text] [Related]
38. Distinct claudin expression characterizes BRCA1-related breast cancer.
Heerma van Voss MR; van Diest PJ; Smolders YH; Bart J; van der Wall E; van der Groep P
Histopathology; 2014 Dec; 65(6):814-27. PubMed ID: 25041042
[TBL] [Abstract][Full Text] [Related]
39. Basal-like subtype of breast cancer: a review of its unique characteristics and their clinical significance.
Kobayashi S
Breast Cancer; 2008; 15(2):153-8. PubMed ID: 18311481
[TBL] [Abstract][Full Text] [Related]
40. Competing endogenous RNA network analysis identifies critical genes among the different breast cancer subtypes.
Chen J; Xu J; Li Y; Zhang J; Chen H; Lu J; Wang Z; Zhao X; Xu K; Li Y; Li X; Zhang Y
Oncotarget; 2017 Feb; 8(6):10171-10184. PubMed ID: 28052038
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
